Jakafi 10 mg (Ruxolitinib / Rulicent) – Advanced JAK Inhibitor for Myeloproliferative Disorders
Jakafi 10 mg, containing the active ingredient Ruxolitinib, is a breakthrough therapy used to treat several serious blood-related disorders. Classified as a Janus Kinase (JAK1/JAK2) inhibitor, it works by controlling abnormal blood cell production and reducing inflammation within the bone marrow.
Rulicent 10 mg is a trusted generic alternative offering similar therapeutic benefits at a more accessible cost, widely prescribed in oncology and hematology practices worldwide.
This medication is especially effective in treating myelofibrosis, polycythemia vera, and certain types of graft-versus-host disease (GVHD). Patients taking Ruxolitinib often experience significant relief from symptoms such as enlarged spleen, night sweats, bone pain, fatigue, and weight loss.
⭐ How Ruxolitinib Works
Many myeloproliferative disorders are caused by overactive signaling in the JAK pathway.
Ruxolitinib 10 mg blocks JAK1 and JAK2 enzymes, helping to:
-
Reduce excessive blood cell production
-
Shrink an enlarged spleen
-
Lower inflammatory cytokines
-
Improve anemia and energy levels
-
Control disease progression
This targeted action provides long-term symptom relief and enhances quality of life.
⭐ Key Benefits
-
Particularly effective for myelofibrosis
-
Helps control high red blood cell counts in polycythemia vera
-
Beneficial for steroid-refractory GVHD
-
Reduces spleen size and related discomfort
-
Improves strength, appetite, and overall well-being
-
Oral tablet for convenient daily dosing
⭐ How to Use
-
Typical dosing: One 10 mg tablet twice daily, or as prescribed
-
Dosage is based on blood counts and clinical condition
-
Take with or without food
-
Do not stop or modify the dose without medical advice
Regular blood monitoring is essential during treatment.
⭐ Possible Side Effects
Most common:
-
Anemia
-
Low platelet count
-
Dizziness
-
Headache
-
Mild bruising
Less common but serious:
-
Increased infection risk
-
Elevated liver enzymes
-
Shingles activation
Report unusual fatigue, fever, or bleeding to a healthcare provider.
⭐ Who Should Use Jakafi / Ruxolitinib
-
Patients diagnosed with intermediate to high-risk myelofibrosis
-
Individuals with polycythemia vera resistant to hydroxyurea
-
Patients with acute or chronic GVHD unresponsive to steroids
-
Adults requiring targeted JAK inhibition therapy
⭐ Storage Instructions
-
Store below 30°C
-
Keep in original packaging
-
Protect from moisture and direct sunlight
-
Keep out of reach of children
